Announcement

Collapse
No announcement yet.

Respiration . Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Respiration . Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial


    Respiration


    . 2021 Jan 22;1-11.
    doi: 10.1159/000512063. Online ahead of print.
    Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial


    Xiao Tang 1 , Ying-Mei Feng 2 , Ji-Xiang Ni 3 , Jia-Ying Zhang 2 , Li-Min Liu 4 , Ke Hu 5 , Xiu-Zhi Wu 6 , Ji-Xian Zhang 7 , Jun-Wen Chen 8 , Jian-Chu Zhang 9 , Jian Su 3 , Yu-Lei Li 4 , Yang Zhao 5 , Jiao Xie 7 , Zhou Ding 8 , Xin-Liang He 9 , Wen Wang 6 , Rong-Hua Jin 2 , Huan-Zhong Shi 6 , Bing Sun 6



    Affiliations

    Abstract

    Background: There is still no clinical evidence available to support or to oppose corticosteroid treatment for coronavirus disease 2019 (COVID-19) pneumonia.
    Objective: To investigate the efficacy and safety of corticosteroid given to the hospitalized patients with COVID-19 pneumonia.
    Methods: This was a prospective, multicenter, single-blind, randomized control trial. Adult patients with COVID-19 pneumonia who were admitted to the general ward were randomly assigned to either receive methylprednisolone or not for 7 days. The primary end point was the incidence of clinical deterioration 14 days after randomization.
    Results: We terminated this trial early because the number of patients with COVID-19 pneumonia in all the centers decreased in late March. Finally, a total of 86 COVID-19 patients underwent randomization. There was no difference of the incidence of clinical deterioration between the methylprednisolone group and control group (4.8 vs. 4.8%, p = 1.000). The duration of throat viral RNA detectability in the methylprednisolone group was 11 days (interquartile range, 6-16 days), which was significantly longer than that in the control group (8 days [2-12 days], p = 0.030). There were no significant differences between the 2 groups in other secondary outcomes. Mass cytometry discovered CD3+ T cells, CD8+ T cells, and NK cells in the methylprednisolone group which were significantly lower than those in the control group after randomization (p < 0.05).
    Conclusions: From this prematurely closed trial, we found that the short-term early use of corticosteroid could suppress the immune cells, which may prolong severe acute respiratory syndrome coronavirus 2 shedding in patients with COVID-19 pneumonia.
    Trial registration: ClinicalTrials.gov, NCT04273321.

    Keywords: Coronavirus disease 2019; Corticosteroid; Outcome; Pneumonia; Virus shedding.

Working...
X